Ocular Surgery News

10/21/2026

INDUSTRY NEWS: 📣

for wet age-related macular degeneration fails to meet primary endpoint in phase 3 LUCIA trial.

Read more on Healio:🔗

A second pivotal phase 3 trial of Duravyu in wet age-related macular degeneration failed to meet its primary endpoint, according to a press release from EyePoint Pharmaceuticals.

10/20/2026

Every is vulnerable to repetitive strain injury.

To sustain a long and rewarding career, management of both is critically important, according to Dr. Richard Lindstrom.

Read his key tips gathered across 5 decades as a busy surgeon: 🔗

Practicing ophthalmology is mentally and physically stressful. To sustain a long and rewarding career, management of both is critically important. The cover story in this issue of Healio | OSN focuses on physical stress.

10/20/2026

, cardiovascular health and social factors can impact risk.

Read more from Healio's coverage of :🔗

https://vist.ly/5p8eh

American Academy of Ophthalmology

NEW ORLEANS — Although polygenic risk scores can be a useful tool in glaucoma, ophthalmologists should also be aware of patient lifestyle and environmental factors, according to a presenter. “We all routinely encounter patients in our clinics who have a relative who has lost their vision from gl...

10/20/2026

After years of repetitive movements as a , it's not easy to fix damage to the body.

That is why it is essential for younger to prioritize healthy habits.

Dr. Sam Garg shares tips and tricks for combatting pain in the OR:🔗

Now that I am in the middle of my career and approaching 51 years old, I feel like my body does not bounce back as well as it used to.

10/19/2026

“These are tough patients that we now have more insights on maybe using a long-acting depot drug like fluocinolone 0.18 mg.”

Dr. David Almeida discusses fluocinolone acetonide 0.18 mg for noninfectious posterior segment .

Read more: 🔗

https://vist.ly/5p3xm

10/19/2026

For , occupational pain can start early.👀

In this Healio exclusive feature, experts dive into how good can save doctors from all specialties from musculoskeletal pain and injuries.

Preserve your body for a long career!🔗

For ophthalmologists, occupational pain can start early. For Cynthia Matossian, MD, FACS, discomfort arose fewer than 5 years into her career. She said surgeons often find themselves in similar positions over the course of their routine work, and repeated motions can wear people down.

10/19/2026

‼️New Approval‼️

The approved a supplemental new drug application for , a preservative-free , for the treatment of .

Find out more on Healio:🔗

The FDA approved a supplemental new drug application for Ryzumvi, a preservative-free eye drop, for the treatment of presbyopia.“Presbyopia affects approximately 90% of Americans over age 45, making everyday activities like reading, using smartphones and working on computers increasingly diffi...

10/18/2026

In a new edition of Grand Rounds at New England Eye Center:

A 35-year-old woman was referred for a neuro- evaluation for left optic disc edema and transient visual symptoms in the left .

OCT was normal. Crack the case! 👀

A 35-year-old woman was referred by her optometrist for a neuro-ophthalmology evaluation for left optic disc edema and transient visual symptoms in the left eye.Her medical and ocular histories were notable for elevated BMI but were otherwise unremarkable. She was not taking any prescribed or over-t...

10/17/2026

Bausch + Lomb named Thomas J. Appio interim CEO, replacing Brent Saunders.

Dr. Darrell E. White provides commentary on what the move may suggest about Bausch + Lomb’s future.

Read more on Healio: 🔗

Bausch + Lomb and Bausch Health Companies announced Oct. 12 that Thomas J. Appio was named interim CEO, taking over the role from Brent Saunders.The only thing surprising about this announcement is the timing.

10/16/2026

‼️BREAKING‼️

The approved , an interleukin-6 inhibitor, for at-home subcutaneous treatment of , according to a press release from Genentech.

Read more on Healio:🔗

The FDA approved Enspryng, an interleukin-6 inhibitor, for at-home subcutaneous treatment of thyroid eye disease, according to a press release from Genentech.